Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery when taken ...
Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.
News Medical on MSN3d
AstraZeneca receives positive NICE recommendations for lung cancer treatmentAstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...
Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...
GB News on MSN7d
Cancer breakthrough: Daily pill which can DOUBLE survival time of lung cancer patients to be made available on NHSA breakthrough daily pill which doubles the survival time for certain lung cancer patients will now be routinely available on ...
UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...
During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.
The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...
A DAILY pill that doubles survival time for lung cancer patients will be made routinely available on the NHS. Osimertinib, also known as Tagrisso and made by AstraZeneca, helps prevent cancer from ...
During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...
AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) ...
Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback